Final hours! Save up to 55% OFF InvestingProCLAIM SALE

General Atlantic to invest $55 million in Indonesia's Kalbe Farma biotech JV

Published 01/27/2021, 12:10 AM
Updated 01/27/2021, 12:15 AM
© Reuters.

SINGAPORE (Reuters) - Global private equity firm General Atlantic will invest $55 million in Kalbe Genexine Biologics (KGBio), a joint venture of Indonesian pharmaceuticals firm PT Kalbe Farma and South Korean biotech firm Genexine Inc.

The investment will go towards KGBio's ongoing clinical development and help boost its production capacity, among others, the companies said in a joint statement on Wednesday.

"As a global player in life sciences, General Atlantic brings an extensive network and deep expertise in innovation that KGBio aims to leverage," said Sie Djohan, director of Kalbe Farma and chief exectuive officer of KGBio.

Kalbe Farma owns a majority stake in KGBio, founded in 2016. Kalbe Farma, which operates in prescription pharmaceuticals, consumer health, nutrition, and distribution and logistics, has a market value of $5.2 billion.

U.S.-based General Atlantic has invested in many life sciences firms over several decades, focusing on both revenue-stage and emerging growth pharmaceutical and biotechnology businesses.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.